Literature DB >> 24529715

Patterns of local-regional failure in completely resected stage IIIA(N2) non-small cell lung cancer cases: implications for postoperative radiation therapy clinical target volume design.

Wen Feng1, Xiao-Long Fu2, Xu-Wei Cai1, Huan-Jun Yang1, Kai-Liang Wu1, Min Fan1, Jia-Qing Xiang3, Ya-Wei Zhang3, Hai-Quan Chen3.   

Abstract

PURPOSE: To analyze patterns of local-regional failure (LRF) for completely resected stage IIIA(N2) non-small cell lung cancer (NSCLC) patients treated in our hospital and to propose a clinical target volume (CTV) for postoperative radiation therapy (PORT) in these patients. METHODS AND MATERIALS: From 2005 to 2011, consecutive patients with pT1-3N2 NSCLC who underwent complete resection in our hospital but who did not receive PORT were identified. The patterns of first LRF were assessed and evaluated as to whether these areas would be encompassed by our proposed PORT CTV.
RESULTS: With a median follow-up of 24 months, 173 of 250 patients (69.2%) experienced disease recurrence. Of the 54 patients with LRF as the first event, 48 (89%) had recurrence within the proposed PORT CTV, and 6 (11%) had failures occurring both within and outside the proposed CTV (all of which occurred in patients with right-lung cancer). Ninety-three percent of failure sites (104 of 112) would have been contained within the proposed PORT CTV. For left-sided lung cancer, the most common lymph node station failure site was 4R, followed by 7, 4L, 6, 10L, and 5. For right-sided lung cancer, the most common site was station 2R, followed by 10R, 4R, and 7.
CONCLUSIONS: LRF following complete surgery was an important and potentially preventable pattern of failure in stage IIIA(N2) patients. Ipsilateral superior mediastinal recurrences dominated for right-sided tumors, whereas left-sided tumors frequently involved the bilateral superior mediastinum. Most of the LRF sites would have been covered by the proposed PORT CTV. A prospective investigation of patterns of failure after PORT (following our proposed CTV delineation guideline) is presently underway and will be reported in a separate analysis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24529715     DOI: 10.1016/j.ijrobp.2013.12.048

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  22 in total

1.  Salvage Photon or Proton Radiotherapy for Oligo-recurrence in Regional Lymph Nodes After Surgery for Non-small Cell Lung Cancer.

Authors:  Masatoshi Nakamura; Kayoko Ohnishi; Hitoshi Ishikawa; Kensuke Nakazawa; Toshihiro Shiozawa; Toshiyuki Okumura; Ikuo Sekine; Yukio Sato; Nobuyuki Hizawa; Hideyuki Sakurai
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Tri-modality treatment in N2 stage IIIa non-small cell lung cancer: proper sequence remains unknown.

Authors:  Ze-Rui Zhao; Calvin S H Ng
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

3.  Causes of death and subsequent treatment after initial radical or palliative therapy of stage III non-small-cell lung cancer.

Authors:  A G Robinson; K Young; K Balchin; A Ashworth; T Owen
Journal:  Curr Oncol       Date:  2015-10       Impact factor: 3.677

Review 4.  Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Authors:  A Gómez; J A González; F Couñago; C Vallejo; F Casas; N Rodríguez de Dios
Journal:  Clin Transl Oncol       Date:  2015-08-18       Impact factor: 3.405

5.  Radiation pneumonitis in lung cancer treated with volumetric modulated arc therapy.

Authors:  Kan Wu; Xiao Xu; Xiadong Li; Jiahao Wang; Lucheng Zhu; Xueqin Chen; Bing Wang; Minna Zhang; Bing Xia; Shenglin Ma
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

6.  The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume.

Authors:  Wen Feng; Qin Zhang; Xiao-Long Fu; Xu-Wei Cai; Zheng-Fei Zhu; Huan-Jun Yang; Jia-Qing Xiang; Ya-Wei Zhang; Hai-Quan Chen
Journal:  BMC Cancer       Date:  2015-05-02       Impact factor: 4.430

7.  Delineation of clinical target volume for postoperative radiotherapy in stage IIIA-pN2 non-small-cell lung cancer.

Authors:  Xuquan Jing; Xue Meng; Xindong Sun; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-02-19       Impact factor: 4.147

8.  Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis.

Authors:  Vasileios Askoxylakis; Judith Tanner; Jutta Kappes; Hans Hoffmann; Nils H Nicolay; Harald Rief; Juergen Debus; Michael Thomas; Marc Bischof
Journal:  BMC Cancer       Date:  2014-08-07       Impact factor: 4.430

9.  Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.

Authors:  Wen Feng; Yuan Li; Lei Shen; Xu-Wei Cai; Zheng-Fei Zhu; Jian-Hua Chang; Jia-Qing Xiang; Ya-Wei Zhang; Hai-Quan Chen; Xiao-Long Fu
Journal:  Oncotarget       Date:  2016-02-09

10.  Early postoperative radiotherapy is associated with improved outcomes over late postoperative radiotherapy in the management of completely resected (R0) Stage IIIA-N2 non-small cell lung cancer.

Authors:  Huan-Huan Wang; Lei Deng; Qing-Lian Wen; Chun-Ze Zhang; Nicholas G Zaorsky; Bai-Lin Zhang; Jie Chen; Xian-Liang Zeng; Yao-Li Cui; Yang-Yang Shi; Hai-Ling Hou; Wei Wang; Bo Jiang; Jun Wang; Qing-Song Pang; Lu-Jun Zhao; Zhi-Yong Yuan; Ping Wang; Mao-Bin Meng
Journal:  Oncotarget       Date:  2017-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.